Key Inclusion Criteria:

          -  Male or female patients ≥18 years of age who are HLA-A*02+

          -  Histologically confirmed incurable or metastatic solid tumors that are HPV16+

          -  Cancer must have progressed after at least 1 available standard therapy for incurable
             disease, or the patient is intolerant to or refuses standard therapy(ies) or has a
             tumor for which no standard therapy(ies) exist

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1

          -  At least 1 measurable lesion according to RECIST 1.1

          -  Must have a lesion that can be biopsied with acceptable clinical risk and agree to
             have a fresh biopsy at Baseline and on Cycle 2 Day 8 (+/- 3 days)

          -  Patients must agree to venous access for the leukapheresis and be willing to have a
             central line inserted if venous access is an issue

          -  Adequate organ function and bone marrow reserve performed within 14 days prior to the
             leukapheresis

        Exclusion Criteria:

          -  Treatment with anticancer therapy, including investigational therapy, within 2 weeks
             prior to leukapheresis. For prior therapies with a half-life longer than 3 days,
             discontinuation of the therapy must have occurred at least 28 days prior to
             leukapheresis

          -  Systemic treatment with either corticosteroids (>10 mg of prednisone or the equivalent
             per day) or other immunosuppressive medications within 14 days prior to leukapheresis

          -  Patients treated with non-corticosteroid based immunosuppressive agents within the
             last 6 months may not be eligible and should be discussed with the Sponsor

          -  Patients with active, known, or suspected autoimmune disease may not be eligible and
             should be discussed with the Sponsor

          -  Patients with >Grade 1 AEs related to previous treatment with anticancer or
             investigational therapy that do not resolve at least 2 weeks prior to leukapheresis,
             except Grade 2 alopecia

          -  Known active hepatitis B or hepatitis C, or active mycobacterium tuberculosis
             infection

          -  History of any Grade 4 immune-related AE (irAE) from prior immunotherapy

          -  Has known active central nervous system metastases

          -  History of interstitial lung disease requiring steroids

          -  Significant acute or chronic illness

          -  Major surgery within 2 weeks of leukapheresis